Financial reports
10-Q
2023 Q3
Quarterly report
26 Jan 23
10-Q
2022 Q2
Quarterly report
26 Oct 22
10-Q
2023 Q1
Quarterly report
27 Jul 22
10-K
2022 FY
Annual report
11 May 22
10-Q
2022 Q3
Quarterly report
26 Jan 22
10-Q
2022 Q2
Quarterly report
26 Oct 21
10-Q
2022 Q1
Quarterly report
28 Jul 21
10-K
2021 FY
Annual report
11 May 21
10-Q
2021 Q3
Quarterly report
11 Feb 21
10-Q
2021 Q2
Quarterly report
12 Nov 20
Current reports
8-K
Sumitovant Biopharma Completes Acquisition of Myovant Sciences
10 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
1 Mar 23
8-K
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
26 Jan 23
8-K
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
26 Oct 22
8-K
Entry into a Material Definitive Agreement
24 Oct 22
8-K
Submission of Matters to a Vote of Security Holders
21 Oct 22
8-K
Other Events
3 Oct 22
8-K
Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
27 Jul 22
8-K
Results of Operations and Financial Condition
10 May 22
8-K
Departure of Directors or Certain Officers
25 Mar 22
Registration and prospectus
15-12G
Securities registration termination
20 Mar 23
25-NSE
Exchange delisting
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
POS AM
Prospectus update (post-effective amendment)
10 Mar 23
Proxies
DEFA14A
Additional proxy soliciting materials
16 Feb 23
DEFA14A
Additional proxy soliciting materials
2 Feb 23
DEFM14A
Proxy related to merger
23 Jan 23
PRER14A
Preliminary revised proxy
6 Jan 23
PREM14A
Preliminary proxy related to merger
8 Dec 22
DEFA14A
Additional proxy soliciting materials
24 Oct 22
DEFA14A
Additional proxy soliciting materials
24 Oct 22
DEFA14A
Additional proxy soliciting materials
27 Jul 22
DEF 14A
Definitive proxy
27 Jul 22
DEFA14A
Additional proxy soliciting materials
28 Jul 21
Other
EFFECT
Notice of effectiveness
17 Mar 23
EFFECT
Notice of effectiveness
17 Mar 23
CT ORDER
Confidential treatment order
2 Feb 23
CORRESP
Correspondence with SEC
6 Jan 23
UPLOAD
Letter from SEC
21 Dec 22
CT ORDER
Confidential treatment order
27 Jul 21
SEC STAFF
SEC staff action: Order
26 Mar 21
SEC STAFF
SEC staff action: Order
26 Feb 21
EFFECT
Notice of effectiveness
7 Aug 20
CT ORDER
Confidential treatment order
1 Oct 18